GW&K Investment Management’s Standard BioTools LAB Stock Holding History

GW&K Investment Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-115	Closed	–	–	547
2022 Q4	$0	Buy	+115	New	+$142	﹤0.01%	475

Other funds holding LAB

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

GW&K Investment Management's LAB Position: Q1 2023 in Review

GW&K Investment Management sold out of Standard BioTools (LAB) in Q1 2023, closing a stake of 115 shares.

GW&K Investment Management first reported a position in LAB in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 69 funds tracked by Wall St. Rank hold LAB as of Q1 2023.

GW&K Investment Management reported no remaining Standard BioTools position as of Q1 2023 after selling out during the quarter.
GW&K Investment Management sold 115 Standard BioTools shares in Q1 2023.
GW&K Investment Management first reported a position in Standard BioTools in Q4 2022 and held it in 1 quarter.
GW&K Investment Management's Standard BioTools position peaked at $0 in Q4 2022.
69 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2023.

Based on GW&K Investment Management's 13F filing for Q1 2023, filed 9 May 2023.